What is the core difference between semaglutide and tirzepatide?
Both are once-weekly injectable drugs in the incretin class, and both are FDA-approved for type 2 diabetes and for chronic weight management. The mechanistic difference is receptor count: semaglutide activates one receptor (GLP-1), while tirzepatide activates two (GIP and GLP-1).
That added GIP activity is the leading explanation for why tirzepatide tends to produce greater weight loss. GLP-1 drives appetite suppression, slowed gastric emptying, and glucose-dependent insulin release; adding GIP appears to amplify the metabolic effect. In branded terms, semaglutide is sold as Ozempic and Wegovy, and tirzepatide as Mounjaro and Zepbound.
What did the head-to-head SURMOUNT-5 trial find?
Unlike most drug comparisons, these two were actually tested against each other. SURMOUNT-5 was a randomized phase 3b trial in adults with obesity (without diabetes) that pitted tirzepatide directly against semaglutide, each titrated to its maximum tolerated dose over 72 weeks.
Tirzepatide was superior: a mean weight reduction of about 20.2% versus 13.7% for semaglutide — roughly a 6.5 percentage-point advantage, statistically significant at P<0.001. Nearly 20% of tirzepatide participants lost at least 30% of their body weight, compared with about 7% on semaglutide. This is the strongest evidence available that, on weight loss alone, the dual agonist edges out the single agonist.
How do the side effects compare?
Both drugs share the incretin-class side-effect profile, which is dominated by gastrointestinal effects — nausea, diarrhea, vomiting, and constipation — that are worst during dose escalation and tend to ease over time.
The profiles differ in emphasis. Semaglutide skews toward more nausea and constipation; tirzepatide skews toward more diarrhea with somewhat less nausea. In the head-to-head SURMOUNT-5 trial, tirzepatide also showed a lower rate of discontinuation for adverse events. Neither is a clear "gentler" option for everyone — tolerance is individual, which is why both are escalated slowly.
Which should someone choose?
On weight loss, the head-to-head data favor tirzepatide. But "more weight loss" is not the only axis: cost and insurance coverage, the specific indication (diabetes vs obesity vs sleep apnea), tolerability for a given person, and prescriber familiarity all matter. Both are approved, both have large evidence bases, and both are legitimate, prescribable options.
This is a clinician's call, not a self-directed one. The decision belongs in a conversation with a licensed prescriber who can weigh the individual's history, comorbidities, and goals.
Tracking either compound on PeptidePanel
Whichever a clinician prescribes, the monitoring work is identical: log doses, follow the biomarkers that matter (HbA1c, lipids, weight trend), and catch side effects early during titration. PeptidePanel is the neutral tracking layer for that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
PeptidePanel does not sell, source, supply, or prescribe any compound. It is a monitoring tool for protocols a qualified prescriber has put you on.